A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 130,306 shares of VKTX stock, worth $8.58 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
130,306
Previous 96,905 34.47%
Holding current value
$8.58 Million
Previous $5.14 Million 60.61%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$49.84 - $70.47 $1.66 Million - $2.35 Million
33,401 Added 34.47%
130,306 $8.25 Million
Q2 2024

Jul 19, 2024

SELL
$47.39 - $80.2 $47,342 - $80,119
-999 Reduced 1.02%
96,905 $5.14 Million
Q1 2024

Apr 22, 2024

SELL
$17.4 - $94.5 $862,135 - $4.68 Million
-49,548 Reduced 33.6%
97,904 $8.03 Million
Q4 2023

Jan 16, 2024

BUY
$9.24 - $19.64 $121,016 - $257,225
13,097 Added 9.75%
147,452 $2.74 Million
Q3 2023

Oct 24, 2023

SELL
$10.92 - $16.0 $96,631 - $141,584
-8,849 Reduced 6.18%
134,355 $1.49 Million
Q2 2023

Jul 25, 2023

BUY
$14.84 - $24.79 $591,477 - $988,055
39,857 Added 38.57%
143,204 $2.32 Million
Q1 2023

Apr 14, 2023

SELL
$8.08 - $17.33 $204,908 - $439,488
-25,360 Reduced 19.7%
103,347 $1.72 Million
Q4 2022

Feb 08, 2023

SELL
$2.72 - $9.4 $39,440 - $136,300
-14,500 Reduced 10.13%
128,707 $1.21 Million
Q3 2022

Oct 25, 2022

BUY
$2.55 - $3.89 $4,146 - $6,325
1,626 Added 1.15%
143,207 $390,000
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $6,226 - $9,295
-2,951 Reduced 2.04%
141,581 $409,000
Q1 2022

May 11, 2022

SELL
$3.0 - $4.88 $96,351 - $156,730
-32,117 Reduced 18.18%
144,532 $434,000
Q4 2021

Feb 08, 2022

SELL
$4.6 - $6.72 $22,420 - $32,753
-4,874 Reduced 2.69%
176,649 $813,000
Q3 2021

Nov 02, 2021

BUY
$5.58 - $7.04 $105,238 - $132,774
18,860 Added 11.59%
181,523 $1.14 Million
Q2 2021

Aug 11, 2021

SELL
$5.19 - $6.73 $3,996 - $5,182
-770 Reduced 0.47%
162,663 $974,000
Q1 2021

May 14, 2021

BUY
$5.74 - $9.67 $164,095 - $276,445
28,588 Added 21.2%
163,433 $1.03 Million
Q4 2020

Feb 12, 2021

BUY
$5.3 - $6.71 $113,976 - $144,298
21,505 Added 18.97%
134,845 $759,000
Q3 2020

Nov 04, 2020

SELL
$5.73 - $8.11 $56,142 - $79,461
-9,798 Reduced 7.96%
113,340 $660,000
Q2 2020

Jul 17, 2020

BUY
$4.35 - $8.08 $170,241 - $316,218
39,136 Added 46.59%
123,138 $888,000
Q1 2020

Apr 21, 2020

BUY
$3.45 - $7.95 $43,656 - $100,599
12,654 Added 17.74%
84,002 $393,000
Q4 2019

Feb 12, 2020

SELL
$6.38 - $8.73 $1,920 - $2,627
-301 Reduced 0.42%
71,348 $572,000
Q3 2019

Nov 07, 2019

BUY
$6.55 - $8.6 $158,320 - $207,870
24,171 Added 50.91%
71,649 $493,000
Q2 2019

Aug 06, 2019

BUY
$7.67 - $10.63 $97,899 - $135,681
12,764 Added 36.77%
47,478 $394,000
Q1 2019

May 06, 2019

BUY
$7.58 - $9.94 $94,393 - $123,782
12,453 Added 55.94%
34,714 $345,000
Q4 2018

Feb 11, 2019

BUY
$7.16 - $16.21 $159,388 - $360,850
22,261 New
22,261 $170,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.